Azitra Inc Announces Positive Phase 1b Trial Results

Azitra Inc ( (AZTR) ) has shared an update.

On June 17, 2025, Azitra, Inc. announced promising safety data from its Phase 1b clinical trial for ATR12-351, a live biotherapeutic candidate targeting Netherton syndrome. The trial, which is halfway enrolled, showed that ATR12-351 was generally safe and well-tolerated, with only mild to moderate application site reactions reported. This milestone marks significant progress in Azitra’s mission to bring ATR12-351 to market, potentially offering a life-changing treatment for those affected by this rare skin condition.

The most recent analyst rating on (AZTR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Spark’s Take on AZTR Stock

According to Spark, TipRanks’ AI Analyst, AZTR is a Underperform.

Azitra Inc’s overall stock score is primarily impacted by its strong revenue growth but is heavily weighed down by substantial financial losses and negative cash flows. The technical analysis suggests bearish momentum, and the negative P/E ratio indicates market concerns about profitability. These factors contribute to a low overall stock score.

To see Spark’s full report on AZTR stock, click here.

More about Azitra Inc

Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Its lead program, ATR-12, aims to treat Netherton syndrome, a rare and chronic skin disease with no approved treatments. Azitra also has a program, ATR-04, targeting EGFR inhibitor-associated skin toxicity, with a Phase 1/2 clinical trial underway.

Average Trading Volume: 1,466,533

Technical Sentiment Signal: Sell

See more insights into AZTR stock on TipRanks’ Stock Analysis page.